TBPH — Theravance Biopharma Balance Sheet
0.000.00%
Last trade - 00:00
- $398.23m
- $331.21m
- $57.42m
- 30
- 27
- 53
- 30
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 281 | 293 | 173 | 327 | 102 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 50.6 | 69.7 | 57.6 | 16.8 | 17.5 |
Prepaid Expenses | |||||
Total Current Assets | 338 | 393 | 250 | 353 | 134 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 59.2 | 59.7 | 53.3 | 52 | 45.4 |
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 409 | 469 | 375 | 607 | 382 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 112 | 124 | 58.6 | 28.7 | 24.8 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 633 | 773 | 713 | 166 | 169 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -224 | -304 | -339 | 442 | 213 |
Total Liabilities & Shareholders' Equity | 409 | 469 | 375 | 607 | 382 |
Total Common Shares Outstanding |